The Collaborative Wilms Tumour Africa Project; Baseline evaluation of Wilms tumour treatment and outcome in eight institutes in sub-Saharan Africa

Paintsil, Vivian; David, Haileyesus; Kambugu, Joyce; Renner, Lorna; Kouya, Francine; Eden, Tim; Hesseling, Peter; Molyneux, Elizabeth; Israëls, Trijn

doi:10.1016/j.ejca.2014.10.030

Cited by 62 publications

(64 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study has shown an overall 5‐year survival of 53.3% among cases that were available for evaluation in our setting. Compared with the previous report in this setting in 2006 and some other developing countries, this may be a modest improvement. Nonetheless, the abandonment‐sensitive survival of 35.6% is substantially lower than the reported overall survival of more than 80% from most developed countries and may be a manifestation of vast inequalities in pediatric cancer care.…”

Section: Discussioncontrasting

confidence: 62%

“…Another therapeutic modification that might further improve outcome in our setting with large tumors at presentation and limited supportive care may be the routine use of preoperative chemotherapy in our cases. The result of a collaborative study from some other African countries might support this.…”

Section: Discussionmentioning

confidence: 88%

“…More importantly, facility for radiotherapy is indispensable for the therapy of unfavorable histology variants and late‐stage WT. These facilities are lacking in our setting and some other developing countries, and where they are available, the cost might be prohibitive to some patients and their families. The absence of radiotherapy was a major drawback in our management and all cases that required this therapy in the present report could not access it.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Continuing barriers to care of Wilms tumor in a low‐income country

Ekenze

Nwangwu

Ezomike

et al. 2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 62%

Section: Discussionmentioning

confidence: 88%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Continuing barriers to care of Wilms tumor in a low‐income country

Ekenze

Nwangwu

Ezomike

et al. 2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…A baseline evaluation was carried out in participating centres prior to the implementation of the treatment guideline . This baseline evaluation documented the end‐of‐treatment outcome of patients and existing facilities and practices in each centre, including details on supportive care and abandonment‐related aspects …”

Section: Methodsmentioning

confidence: 99%

Improved outcome at end of treatment in the collaborative Wilms tumour Africa project

Israëls

Paintsil

Nyirenda

et al. 2018

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Current and former personnel from MBH have successfully collaborated on numerous national and international research investigations. [62][63][64][65][66][67] The pre-existing infrastructure present at both sites, combined with personal knowledge and established relations between study sites, allows for study feasibility and anticipated success.…”

Section: Discussionmentioning

confidence: 99%

Subdissociative intranasal ketamine plus standard pain therapy versus standard pain therapy in the treatment of paediatric sickle cell disease vaso-occlusive crises in resource-limited settings: study protocol for a randomised controlled trial

et al. 2017

View full text Add to dashboard Cite

IntroductionPediatric sickle cell disease, highly prevalent in sub-Saharan Africa, carries great morbidity and mortality risk. Limited resources and monitoring make management of acute vaso-occlusive crises challenging. This study aims to evaluate the efficacy and safety of subdissociative intranasal ketamine as a cheap, readily available and easily administered adjunct to standard pain therapy. We hypothesise that subdissociative, intranasal ketamine may significantly augment current approaches to pain management in resource-limited settings in a safe and cost-effective manner.Methods and analysisThis is a multicentred, randomised, double-blind, placebo-controlled trial enrolling children 4–16 years of age with sickle cell disease and painful vaso-occlusive pain crises. Study sites include two sub-Saharan teaching and referral hospitals with acute intake areas. All patients receive standard analgesic therapy during evaluation. Patients randomised to the treatment arm receive 1 mg/kg intranasal ketamine at onset of therapy, while placebo arm participants receive volume-matched intranasal normal saline. All participants and clinical staff are blinded to the treatment allocation. Data will be analysed on an intention-to-treat basis. Primary endpoints are changes in self-report pain scales (Faces Pain Scale-Revised) at 30, 60 and 120 minutes and rates of adverse events. Secondary endpoints include hospital length of stay, total analgesia use and quality of life assessment 2–3 weeks postintervention.Ethics and disseminationThe research methods for this study have been approved by the Cameroon Baptist Convention Health Board Institutional Review Board (IRB2015-07), the Tanzanian National Institute for Medical Research (NIMR/HQ/R.8a/Vol. IX/2299), Muhimbili National Hospital IRB (MNH/IRB/I/2015/14) and the Tanzanian Food and Drugs Authority (TFDA0015/CTR/0015/9). Data reports will be provided to the Data and Safety Monitoring Board (DSMB) periodically throughout the study as well as all reports of adverse events. All protocol amendments will also be reviewed by the DSMB. Study results, regardless of direction or amplitude, will be submitted for publication in relevant peer-reviewed journals.Trial registrationClinicalTrials.Gov, NCT02573714. Date of registration: 8 October 2015. Pre-results.

show abstract

The Collaborative Wilms Tumour Africa Project; Baseline evaluation of Wilms tumour treatment and outcome in eight institutes in sub-Saharan Africa

Cited by 62 publications

References 16 publications

Continuing barriers to care of Wilms tumor in a low‐income country

Continuing barriers to care of Wilms tumor in a low‐income country

Improved outcome at end of treatment in the collaborative Wilms tumour Africa project

Subdissociative intranasal ketamine plus standard pain therapy versus standard pain therapy in the treatment of paediatric sickle cell disease vaso-occlusive crises in resource-limited settings: study protocol for a randomised controlled trial

Contact Info

Product

Resources

About